GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases. Our translational disease-driven research approach is based on strong expertise, featuring in-house knowledge of drug and diagnostic design and development. A pioneer in the field of nuclear receptor-based drug discovery, GENFIT has a rich history and strong scientific heritage spanning more than two decades. This approach, along with our strong bioinformatics capabilities, enables us to discover and develop drug candidates and diagnostic technologies. Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT, and has played a key role in shaping our company’s expertise over the years. Today, he is chair of the Scientific Advisory Board, lending his unique experience and essential know-how, and supporting our role as an innovative leader in the discovery of solutions for the field.